Obesity and Pharmacological Treatment

  • Bjørn Richelsen

Keywords: Diabetes, Pharmacotherapy, Orlistat, Siblitramine, Rimonabant, Weightloss


Obese Patient Obstructive Sleep Apnoea Excess Body Weight Orlistat Treatment Sulphonylurea Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344:1343–1350, 2001.CrossRefPubMedGoogle Scholar
  2. 2.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:393–403, 2002.CrossRefPubMedGoogle Scholar
  3. 3.
    Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351:2683–2693, 2004.CrossRefPubMedGoogle Scholar
  4. 4.
    Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71–77, 2007.CrossRefPubMedGoogle Scholar
  5. 5.
    Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC: Meta-analysis: pharmacologic treatment of obesity. Ann. Intern. Med. 142:532–546, 2005.PubMedGoogle Scholar
  6. 6.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 353:2111–2120, 2005.CrossRefPubMedGoogle Scholar
  7. 7.
    James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356:2119–2125, 2000.CrossRefPubMedGoogle Scholar
  8. 8.
    Arterburn DE, Crane PK, Veenstra DL: The efficacy and safety of sibutramine for weight loss: a systematic review. Arch. Intern. Med. 164:994–1003, 2004.CrossRefPubMedGoogle Scholar
  9. 9.
    Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid, CH, Lau J: Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews: Reviews 2005 Issue 2 John Wiley and Sons(TRUNCATED), 10.1002/14651858.CD004095.pub2.Google Scholar
  10. 10.
    Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. 27:1437–1446, 2003.CrossRefPubMedGoogle Scholar
  11. 11.
    Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A: Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients: A 3-year randomized, placebo-controlled study. Diabetes Care 30:27–32, 2007.CrossRefPubMedGoogle Scholar
  12. 12.
    Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155–161, 2004.CrossRefPubMedGoogle Scholar
  13. 13.
    Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353:2121–2134, 2005.CrossRefPubMedGoogle Scholar
  14. 14.
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397, 2005.CrossRefPubMedGoogle Scholar
  15. 15.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775, 2006.CrossRefPubMedGoogle Scholar
  16. 16.
    Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660–1672, 2006.CrossRefPubMedGoogle Scholar
  17. 17.
    Henness S, Robinson DM, Lyseng-Williamson KA: Rimonabant. Drugs 66:2109–2119, 2006.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Bjørn Richelsen
    • 1
  1. 1.Department of Medicine and EndocrinologyÅrhus SygehusDenmark

Personalised recommendations